Genmab — November 2018
-
Du mener salg til kurs 1480?
-
Er det ikke i underkanten?
-
Da Winkel på CC talte om nye hurtigere godkendelsesprocedurer tænkte han måske på denne: https://www.fda.gov/AboutFDA/CentersOffices/OfficeofMedicalProductsandTobacco/OCE/ucm612927.htm
-
-
Var der ikke bud fra andre dengang?
-
small Isatuximab trial in Lymphoblastic Leukemia was terminated (Due to an unsatisfactory benefit/risk ratio) https://clinicaltrials.gov/ct2/show/NCT02999633?term=NCT02999633&rank=1
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind